Reflection Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Reflection Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$108K	Buy	+140	New	+$95.1K	0.08%	148

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Reflection Asset Management's REGN Position: Q4 2025 in Review

Reflection Asset Management opened a new position in Regeneron Pharmaceuticals (REGN) in Q4 2025: 140 shares worth $108K. The stake represents 0.08% of the portfolio and ranks #148 among its holdings.

1,388 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

Reflection Asset Management held 140 shares of Regeneron Pharmaceuticals worth $108K as of Q4 2025.
Regeneron Pharmaceuticals was a new Reflection Asset Management position in Q4 2025.
Regeneron Pharmaceuticals made up 0.08% of Reflection Asset Management's portfolio in Q4 2025, its #148 holding.
1,388 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Reflection Asset Management's 13F filing for Q4 2025, filed 2 Mar 2026.